How Clinicians Use Data For Clinical Decision Making March 5, 2003 Anti-Infective Drug Advisory Committee How Clinicians Use Data For Clinical Decision.

Slides:



Advertisements
Similar presentations
Artesunate Rectal Capsules For the initial management of acute malaria in patients who cannot take medication by mouth and for whom parenteral treatment.
Advertisements

Risk of invasive H. influenzae disease in patients with chronic renal failure: a call for vaccination? M. Ulanova, S. Gravelle, N. Hawdon, S. Malik, D.
Acute Otitis Media Trials: Evolution of Guidance Janice Soreth, M.D. Division of Anti-Infective Drug Products January 30, 2001.
Community Acquired Pneumonia Guidelines 2011 Top 11 Recommendations Michael H. Kim.
The Resistance Problem PRSP = Penicillin Resistant Strep. pneumoniae QRSP = Quinolone Resistant Strep. pneumoniae MRSA = Methicillin Resistant Staph.
BETHLEHEM UNIVERSITY Second Neonatal Gathering Fall 2007.
Adriana Weinberg, MD University of Colorado Denver.
Adolescent Vaccines What every parent needs to know!
1 Issues in Selection of Deltas in Non-Inferiority Trials : Acute Bacterial Meningitis and Hospital- Acquired Pneumonia John H. Powers, M.D. Medical Officer.
Pneumococcal Disease and Pneumococcal Vaccines Epidemiology and Prevention of Vaccine- Preventable Diseases National Immunization Program Centers for Disease.
Streptococcus pneumoniae
Challenges in Antibacterial Drug Development Francis P. Tally M.D. Cubist Pharmaceuticals, Inc.
Lecture 3 Antimicrobials and Susceptibility tests Dr. Abdelraouf A. Elmanama Islamic University-Gaza Medical Technology Department.
Microbiologic Surrogate Endpoints in Clinical Trials-IDSA FDA/IDSA/ISAP Workshop April 15, 2004 Sheldon L. Kaplan, MD Baylor College of Medicine Texas.
Office of Drug Evaluation IV, CDER FDA/IDSA/ISAP Workshop 4/16/04 Overview of PK-PD in Drug Development Programs: FDA Perspective FDA/IDSA/ISAP Workshop.
Macrolide-Resistant Streptococcus pneumoniae: What is the Public Health Impact? John H. Powers, M.D. Lead Medical Officer Antimicrobial Drug Development.
Use of antibiotics. Antibiotic use Antimicrobials are the 2 nd most common drugs prescribed by office based physicians In USA1992: 110 million oral antimicrobial.
1 One Year Post-Exclusivity Adverse Event Review: Ertapenem Pediatric Advisory Committee Meeting November 16, 2006 Alan M. Shapiro, MD, PhD, FAAP Medical.
Overview of Use of PK-PD in Streamlining Drug Development William A. Craig Professor of Medicine University of Wisconsin.
Management of Neutropenic Fevers in cancer patients Jerry Yu.
Antimicrobial Stewardship Program JMH House staff Orientation 2012 Lilian Abbo, MD Assistant Professor Clinical Infectious Diseases Laura Smith, PharmD.
Design of Clinical Trials of Antibiotic Therapy for Acute Otitis Media
Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 1 Improvement in Dose Selection: FDA Perspective IDSA/ISAP/FDA Workshop.
TM 2011 Immunization Recommendations H. Cody Meissner, M.D. Professor of Pediatrics Tufts University School of Medicine Boston Floating Hospital for Children.
IDSA / ISAP / FDA Workshop on Antimicrobial Drug Development Update 2004 Edward Cox, MD MPH ODE IV Center for Drug Evaluation and Research US Food and.
Testing People Scientifically.  Clinical trials are research studies in which people help doctors and researchers find ways to improve health care. Each.
Design of Clinical Trials of Antibiotic Therapy for Acute Otitis Media
Rational use of antibiotics in child infection
Jennifer L. Hamilton, MD, PhD, FAAFP, Drexel University College of Medicine Sony P. John, MD, Chester County Hospital.
1 Data from Studies in One Indication Supporting Studies in a Different Indication March 5, 2003 Anti Infective Drugs Advisory Committee Meeting Edward.
PK/PD of Antibiotics in relation to resistance Otto Cars MD Department of Medical Sciences Infectious diseases Uppsala University Sweden.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
Bacteremia and CRBSI as Labeled BSI Indications: A Regulatory History Alfred Sorbello, DO Medical Officer CDER/Division of Anti-Infective Drug Products.
Development of Antibiotics for Otitis Media: Past, Present, and Future Janice Soreth, M.D. Director Division of Anti-Infective Drug Products.
Augmentin ES  for acute otitis media Mamodikoe Makhene, M.D. Prepared for Anti-infectives Advisory Committee meeting January 30, 2001.
Joint Meeting of Anti-Infective Drugs & Drug Safety and Risk Management Advisory Committees December 14-15, 2006 Ketek  (telithromycin) Regulatory History.
STRATEGIES FOR PREVENTION OF CVC INFECTIONS 1) Is chlorhexidine a more effective cutaneous antiseptic agent than povidone-iodine for CVC insertion and.
Antimicrobial Resistance patterns among nosocomial gram negative bacilli by E-test and disc diffusion methods in Sina and Imam Hospital.
FDA Case Studies Pediatric Oncology Subcommittee March 4, 2003.
Clinical Approach to the Diagnosis of SARS Joshua P. Metlay, MD, PhD VA Medical Center Division of General Internal Medicine Center for Clinical Epidemiology.
1 Vaccines and Related Biologic Products Advisory Committee (VRBPAC) May 16, 2007 FluMist ® Influenza Virus Vaccine Live, Intranasal Safety and Effectiveness.
History of Pediatric Labeling
Clinical Trials for Bloodstream Infection / Infective Endocarditis G. Ralph Corey, MD Vance Fowler, MD Duke Clinical Research Institute April 15, 2004.
Hospital Acquired Pneumonia(HAP): is defined as a pneumonia which occurs after 48 hours of admission to hospital. Hospital Acquired Pneumonia(HAP): is.
Center for Drug Evaluation and Research Anti-Infective Drug Advisory Committee March 6, New Drug Application NDA /S-008 Cubicin® (daptomycin.
Antimicrobial Resistance in Streptococcus pneumoniae Implications for Prescription Drug Labeling John H. Powers, MD Lead Medical Officer Antimicrobial.
Treatment of urinary tract infections
Clinical Trials of Acute Otitis Media John Alexander, M.D., M.P.H. Anti-Infective Drugs Advisory Committee November 7, 2001.
Points for Discussion Anti-Infective Drugs Advisory Committee Meeting March 5, 2003.
Acute Otitis Media: Lessons Learned Thomas Smith, M.D. Division of Anti-Infective Drug Products.
Center for Drug Evaluation and Research March 6, 2005 Bacteremia and Endocarditis: Products and Guidance Janice Soreth, MD Director Division of Anti-Infective.
1 One Year Post Exclusivity Adverse Event Review: Ciprofloxacin Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004.
Scientific Basis for Review of Varicella Zoster Immune Globulin Products Blood Products Advisory Committee July 21, 2005 Dorothy Scott, M.D. OBRR/CBER.
Questions to Committee about Potential Cancer Risk with Use of Topical Immunosuppressants (Calcineurin Inhibitors) Question 1: Messages about Risk A. Based.
Acute Bacterial Otitis Media Summary and Charge to the Committee Renata Albrecht, M.D. Division of Special Pathogen and Immunologic Drug Products ODEIV,
1 Zithromax  (Azithromycin) Oral Suspension Single-Dose & 3-day Treatment of Acute Otitis Media Anti-Infective Drugs Advisory Committee November 7, 2001.
1 Developing drugs for resistant pathogens: Problems and possibilities David Ross, M.D., Ph.D. Anti-Infective Drugs Advisory Committee February 20, 2002.
Guideline for the Diagnosis and Management of Adults in LTC with Urinary Tract Infection (Part 2) This is intended as a guide for evidence-based decision-making.
Joint Non-Prescription Drugs and Pediatric Advisory Committee Meeting October 18-19, 2007 Considerations for Extrapolation of Efficacy from Adults to Children.
Tigecycline use in serious nosocomial infections: a drug use evaluation Matteo Bassetti*, Laura Nicolini, Ernestina Repetto, Elda Righi, Valerio Del Bono,
1 Issues in Conduct of Catheter Related Infection (CRI) Studies Charles Knirsch, MD, MPH FDA Anti-infective Advisory Committee Meeting October 14, 2004.
Using Nursing Home Antibiograms To Improve Antibiotic Prescribing and Delivery Training Slides for Nursing Home Nurses Comprehensive Antibiogram Toolkit.
HAP and VAP Guidelines Update
Use of antibiotics.
The Role of the Microbiology Laboratory in AMS programs
Febrile Infant.
Pseudomonas Lung Infections in Cystic Fibrosis
Antibiotic Stewardship
Presentation transcript:

How Clinicians Use Data For Clinical Decision Making March 5, 2003 Anti-Infective Drug Advisory Committee How Clinicians Use Data For Clinical Decision Making March 5, 2003 Anti-Infective Drug Advisory Committee John Bradley, MD Children’s Hospital San Diego

Clinicians’ Use of Data Clinical informationClinical information –Patient being treated –Infection being treated Organism information from cultures (ID and susceptibility)Organism information from cultures (ID and susceptibility) Antibiotic PK, PD, toxicity characteristics of the FDA- approved agents which are active in vitroAntibiotic PK, PD, toxicity characteristics of the FDA- approved agents which are active in vitro

Clinicians’ Use of Data FDAFDA –Review of data on safety and efficacy, with approval only for the particular indications submitted by the sponsor (no new indications for ampicillin!) The medical literature for preferred antibiotic therapyThe medical literature for preferred antibiotic therapy –IDSA guidelines, AAP Redbook Committee, Sanford Guide, published clinical trials, etc.

Clinicians’ Use of Data Patient informationPatient information –Immune competence AgeAge Co-morbiditiesCo-morbidities EtcEtc –Clinical exam, laboratory (organ dysfunction information) and imaging studies

Clinicians’ Use of Data FDA IDSA, others NCCLS CDC Safety and efficacy analysis of submitted data Recommendations for clinicians for treating patients for all infections, all abx Organism ID, and interpretations of susceptibility, based on in vitro testing, and PD Epidemiological evaluation of pathogens (particularly resistant ones)

Clinicians’ Use of Data Example 1:Example 1: –A 12 year old with leukemia with neutropenia and pneumonia, grows Pseudomonas aeruginosa ceftazidime- resistant, meropenem- and ciprofloxacin- susceptible from a bronch wash –I will treat with meropenem based on safety and efficacy in pediatric meningitis, and published adult and pediatric data on clinical efficacy of carbapenems in pneumonia

Clinicians’ Use of Data Example 2 (pre-Haemophilus vaccine):Example 2 (pre-Haemophilus vaccine): –18 month old with periorbital cellulitis and bacteremia (with H. influenzae, type b), is being treated with ceftriaxone –I am asked by a resident why I don’t use i.v. TMP-SMZ, as he frequently uses this drug for H. flu in otitis. –No published series exists on bacteremic infections caused by H. flu, treated with TMP-SMZ. I feel uncomfortable extrapolating from otitis efficacy to sepsis and cellulitis efficacy

When Can You Extrapolate Efficacy? If you can successfully treat a difficult infection, you should be able to treat a simple infectionIf you can successfully treat a difficult infection, you should be able to treat a simple infection

When Can You Extrapolate Efficacy? Some infections are harder to treat based on penetration of antibiotic to the site of infectionSome infections are harder to treat based on penetration of antibiotic to the site of infection –Poor drug penetration (intra-abdominal abscess, meningitis) vs excellent penetration (UTI, pneumonia) Seriousness of infection, spontaneous resolution of infectionSeriousness of infection, spontaneous resolution of infection –Meningitis or pneumonia (Fine Class V) vs. AECB or AOM Co-morbidities of patientsCo-morbidities of patients –Healthy young adult vs neutropenia, old age or neonate

When Can You Extrapolate Safety? Safety of high dose anti-infectives in situations demonstrating borderline drug exposure to a pathogen in infected tissuesSafety of high dose anti-infectives in situations demonstrating borderline drug exposure to a pathogen in infected tissues

When Can You Extrapolate Efficacy? We use published data on safety and efficacy for infections caused by a certain pathogen, consider the host and location of the infection, antibiotic toxicities and in vitro susceptibilities, as well as the risk of failure, to extrapolate efficacy in using an antibiotic which has not been previously studied for the type of infection or the patient population we are treatingWe use published data on safety and efficacy for infections caused by a certain pathogen, consider the host and location of the infection, antibiotic toxicities and in vitro susceptibilities, as well as the risk of failure, to extrapolate efficacy in using an antibiotic which has not been previously studied for the type of infection or the patient population we are treating